Biomedical Engineering for Global Health

Lecture Fifteen

Bioengineering and Ovarian Cancer

Statistics on Ovarian Cancer

United States:

- Incidence: 22,430
- Mortality: 15,280
- Worldwide:
 - Incidence: 190,000
 - Mortality: 114,000


Global Burden of Ovarian Cancer



Risk factors


- Age
 - Most ovarian cancers develop after menopause
- Personal or family history of breast, ovarian, endometrial, prostate or colon cancer.
- Reproductive history


Increases with the more lifetime cycles of ovulation that a woman has undergone. Thus, women who have undergone hormonal treatment for infertility, never used birth control pills, and who never became pregnant are at higher risk for ovarian cancer



Screening of Ovarian Cancer

- Pelvic and rectal exam
- CA125 test
- Transvaginal sonography






Screening Scenarios Scenario #1: Screen 1,000,000 women with CA125 p = .0001 (100 cancers) Se=35%, Sp=98.5% Cost = \$30 Follow with laparoscopy Complication rate = 1% Cost=\$2,000

- TP=35 FP=14,999 Complications=150
- PPV =0.23% NPV =99.99%
- Cost per cancer found = \$1,716,200

Screening Scenarios Scenario #2: Screen 1 000 000 women with transvagina

- Screen 1,000,000 women with transvaginal US
 - P = .0001 (100 cancers)
 - Se=100%, Sp=96%
 - Cost = \$150
- Follow with laparoscopy
 Complication rate = 1%
 - Cost=\$2,000
- TP=100 FP=39,996 Complications=401
- PPV =0.25% NPV =100%
- Cost per cancer found = \$300,672



Screening Scenarios

- Scenario #3 cont.:
 - Screen 1,000,000 women > age 50 with TVUS
 P = .0005 (500 cancers)
 - Se=100%, Sp=??%
 - Cost = \$150
 - How high does Sp need to be for PPV to reach 25%?
 - Sp = 99.985%

Does Ultrasound Screening Work?

- Two studies of over 10,000 low-risk women:
 - The positive predictive value was only 2.6%
 - Ultrasound screening of 100,000 women over age 45 would:
 - Detect 40 cases of ovarian cancer,
 - Result in 5,398 false positives
 - Result in over 160 complications from diagnostic laparoscopy
 - Jacobs I. Screening for early ovarian cancer. Lancet; 2:171-172, 1988.


Ongoing Clinical Trials

United Kingdom

- 200,000 postmenopausal women
 - CA 125 level plus transvaginal ultrasound examination
 Transvaginal ultrasound alone
- No screening
- United States:
 - 37,000 women (aged 55–74)
 - Annual CA 125 level and transvaginal ultrasound examination
 No screening
- Europe:
 - 120,000 postmenopausal women
 - No screening,
 Transvaginal ultrasound at intervals of 18 months
 - Transvaginal ultrasound at intervals of 18 months
 Transvaginal ultrasound at intervals of 3 years

http://www.mja.com.au/public/issues/178 12 160603/and10666 fm.pdf


Ovarian Cancer





Risk factors Detection Treatment Challenges New technologies


Challenge


Better screening methods to detect early stages of ovarian cancer























New screening technologies

- New screening technologies
 - Proteomics
 - DNA microarrays
 - Optical technologies